Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial
NCT07281508
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Cisplatin-related Hearing Loss
Interventions
DRUG:
Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate
Sponsor
The Netherlands Cancer Institute